<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Gastrointest Surg</journal-id><journal-id journal-id-type="iso-abbrev">J. Gastrointest. Surg</journal-id><journal-title-group><journal-title>Journal of Gastrointestinal Surgery</journal-title></journal-title-group><issn pub-type="ppub">1091-255X</issn><issn pub-type="epub">1873-4626</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29766446</article-id><article-id pub-id-type="pmc">6132392</article-id><article-id pub-id-type="publisher-id">3787</article-id><article-id pub-id-type="doi">10.1007/s11605-018-3787-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Prognostic Significance of Post-Operative Morbidity Severity Score After Potentially Curative D2 Gastrectomy for Carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3740-8275</contrib-id><name><surname>Powell</surname><given-names>Arfon</given-names></name><address><phone>02920 743268</phone><email>powella16@cardiff.ac.uk</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Coxon</surname><given-names>Alexandra Harriet</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Patel</surname><given-names>Neil</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chan</surname><given-names>David</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Christian</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>Wyn</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0807 5670</institution-id><institution-id institution-id-type="GRID">grid.5600.3</institution-id><institution>Division of Cancer and Genetics, </institution><institution>Cardiff University, University Hospital of Wales, </institution></institution-wrap>Heath Park, Cardiff, Wales UK </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.273109.e</institution-id><institution>Department of Surgery, </institution><institution>Cardiff &#x00026; Vale University Health Board, </institution></institution-wrap>Cardiff, Wales UK </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.273109.e</institution-id><institution>Department of Pathology, </institution><institution>Cardiff &#x00026; Vale University Health Board, </institution></institution-wrap>Cardiff, Wales UK </aff></contrib-group><pub-date pub-type="epub"><day>15</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="ppub"><year>2018</year></pub-date><volume>22</volume><issue>9</issue><fpage>1516</fpage><lpage>1527</lpage><history><date date-type="received"><day>28</day><month>1</month><year>2018</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Survival and relapse after gastric cancer surgery are largely attributed to tumor biology and surgical radicality; yet, other prognostic factors have been reported, including respiratory sepsis and anastomotic leakage, but not global morbidity severity score (MSS). The hypothesis tested was that MSS would be associated with both disease-free (DFS) and overall survival (OS).</p></sec><sec><title>Methods</title><p id="Par2">Consecutive 373 patients undergoing potentially curative surgery for gastric adenocarcinoma between 2004 and 2016 in a UK cancer network were studied. Complications were defined prospectively as any deviation from a pre-determined post-operative course within 30&#x000a0;days of surgery and classified according to the Clavien-Dindo severity classification (CDSC). Primary outcome measures were DFS and OS.</p></sec><sec><title>Results</title><p id="Par3">Post-operative complications were identified in 127 (34.0%) patients, which was associated with 9 (2.4%) post-operative deaths. Five-year DFS and OS were 35.9 and 38.5% for patients with a post-operative complication compared with 59.5 and 61.5% in controls (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, <italic>p</italic>&#x02009;=&#x02009;0.001, respectively). On multivariable DFS analysis, post-operative morbidity [hazard ratio (HR) 1.63, 95% confidence interval (CI) 1.06&#x02013;2.50, <italic>p</italic>&#x02009;=&#x02009;0.026] was independently associated with poor survival. On multivariable OS analysis, post-operative morbidity HR 2.25 (95% CI 1.04&#x02013;4.85, <italic>p</italic>&#x02009;=&#x02009;0.039) and CDSC HR 1.76 (95% CI 1.35&#x02013;2.29, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) were independently associated with poor survival. These associations were also observed in patients with TNM stage I and II disease with morbidity HR 7.06 (95% CI 1.89&#x02013;26.38, <italic>p</italic>&#x02009;=&#x02009;0.004) and CDSC HR 2.93 (95% CI 1.89&#x02013;4.55, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) offering independent prognostic value.</p></sec><sec><title>Conclusion</title><p id="Par4">Post-operative CDSC was an important independent prognostic factor after potentially curative gastrectomy for carcinoma associated with both DFS and OS. Prehabilitation strategies to minimize complications are warranted.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1007/s11605-018-3787-9) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Gastric cancer</kwd><kwd>Morbidity</kwd><kwd>Complications</kwd><kwd>Survival</kwd></kwd-group><funding-group><award-group><funding-source><institution>Cardiff University</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Society for Surgery of the Alimentary Tract 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Positive versus negative outcomes after surgery are now commonly cited as the definitive measure of surgeon level competence, and certainly, any reasonable observer would surely agree that fatal complications, though uncommon, represent an important measure of outcome at the surgeon, hospital unit, and network level. In contrast, early post-operative morbidity has by tradition been considered to constitute a temporary blip in progress, with no long-term adverse sequelae, other than an associated prolonged duration of hospital stay, and associated short-term, poorer quality of life. Yet, some have contended that such morbidity, particularly after complex major gastrointestinal surgery, is associated with longer-term prognosis, disease relapse, and even cumulative survival.<xref ref-type="bibr" rid="CR1">1</xref><sup>-</sup><xref ref-type="bibr" rid="CR3">3</xref></p><p id="Par6">In global terms, gastric cancer is the third leading cause of cancer-related death, accounting for some 740,000 deaths annually.<xref ref-type="bibr" rid="CR4">4</xref> Surgery remains the only potentially curative treatment, but recurrence and metastasis occur in as many as 20 to 60% of the patients, and survival remains poor even after curative resection. Moreover, such surgery is complex major in nature, inherently high risk, with operative morbidity and mortality cited in the most recent UK National Oesophagogastric Cancer Audits<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref> to be 19.4 and 1.9%, respectively. Gastric cancer relapse and survival are largely attributed to tumor biology, aggressiveness, and the radicality of the surgery<xref ref-type="bibr" rid="CR7">7</xref>, but other prognostic factors have also been reported, in particular anastomotic leakage<xref ref-type="bibr" rid="CR3">3</xref> and sepsis, after surgery for advanced gastric cancer. Why anastomotic leakage affects prognosis remains open to speculation; however, it has been argued that prolonged inflammatory response may promote the metastasis of residual tumor cells. It might also be argued that any stimulus provoking a systemic inflammatory response results in similar adverse outcomes. The aim of this study was to determine if overall post-operative morbidity severity classification might influence prognosis. The hypothesis was that the Clavien-Dindo morbidity severity classification would be associated with both disease-free and overall survival. The setting was a regional UK cancer network serving a population of 1.8 million.</p></sec><sec id="Sec2"><title>Method</title><sec id="Sec3"><title>Patients</title><p id="Par7">In order to test the hypotheses proposed in this study, a single cohort was developed and included patients with radiological TNM stage I to III, who following staging were deemed to have potentially resectable gastric cancer between January 2004 and December 2016. All patients were managed by a multidisciplinary team with an interest in gastric cancer and included surgeons, oncologists, radiologists, anesthetists, and pathologists. Preoperative staging involved computed tomography (CT) of the thorax, abdomen, and pelvis, including staging laparoscopy when considered appropriate, in order to facilitate individually patient-tailored management plans. Selective use of neoadjuvant chemotherapy was adopted following publication of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial<xref ref-type="bibr" rid="CR8">8</xref> in the latter part of the study and was prescribed to 74 patients with minimal comorbidities who were deemed to have relatively advanced disease and would benefit from down-staging of the tumor prior to surgery. Chemotherapy was administered for 3 or 4&#x000a0;cycles preoperatively and post-operatively. Each cycle consisted of epirubicin (50&#x000a0;mg/m<sup>2</sup>) by intravenous bolus, cisplatin (60&#x000a0;mg/m<sup>2</sup>) as a 4-h infusion on day one, and 5-fluorouracil (200&#x000a0;mg/m<sup>2</sup>/day) daily by a continuous intravenous infusion.</p><p id="Par8">The type of surgery for gastric cancer was determined by the anatomical location of the tumor; subtotal gastrectomy was performed in patients with antral tumors, and total gastrectomy was performed in patients with tumors of the cardia (Siewert type III), body, and linitis plastica. A modified extended D2 lymphadenectomy (preserving pancreas and spleen where possible) was performed and the operative approach was open in all cases. In 2010, an enhanced recovery after surgery program was introduced, the details of which have been described previously.<xref ref-type="bibr" rid="CR9">9</xref></p><p id="Par9">Ethical approval was sought, but the chair of Cardiff &#x00026; Value University Health Board ethics committee confirmed that individual patient consent was not required to report clinical outcomes alone, and no formal approval was necessary.</p></sec><sec id="Sec4"><title>Clinicopathological Characteristics</title><p id="Par10">Tumors were staged using the seventh edition of the AJCC/UICC-TNM staging system.<xref ref-type="bibr" rid="CR10">10</xref> Pathological factors were recorded from pathology reports issued at the time of surgery and included tumor differentiation, vascular invasion, margin status, and the number of lymph nodes with and without metastasis.</p><p id="Par11">Complications were defined prospectively as any deviation from a pre-determined post-operative course within 30&#x000a0;days following surgery. Patients undergoing a total gastrectomy underwent a gastrograffin swallow on post-operative day 5 to 7. Complications were diagnosed clinically based on observation, examination, and supplementary investigations including but not limited to blood testing (hematology and biochemistry), radiology, and microbiology. Once identified, complications were classified according to the Clavien-Dindo severity classification (CDSC).<xref ref-type="bibr" rid="CR11">11</xref> Grade I includes patients with any deviation from normal post-operative course. Grade II complications are treated solely by medicinal therapies. Grade III complications require physical intervention. Grade IV complications are deemed life threatening requiring admission to the critical care unit. Grade V represents post-operative death.</p><p id="Par12">Patients were followed up at regular intervals of 3&#x000a0;months for the first year and 6&#x000a0;months thereafter. At each visit, patient underwent physical examination and blood analysis (hematology and biochemistry). Endoscopy and CT were performed when recurrent disease was suspected. In the event that patients developed symptoms suggestive of recurrent disease, investigations were undertaken sooner. Follow-up surveillance was conducted for 5&#x000a0;years or until death whichever was sooner. Death certification was obtained from the Office for National Statistics via Cancer Network Information System Cymru (CaNISC). Patterns of recurrence were defined as locoregional, distant (metastatic), or both locoregional and distant, when both were diagnosed at the same time. The time of recurrence was taken as the date of the confirmatory investigation.</p></sec><sec id="Sec5"><title>Statistical Analysis</title><sec id="Sec6"><title>Justification of Sample Size</title><p id="Par13">Sample size calculations were based on a pre study literature survey of (CRUK cancers statistics reference), which indicated that the baseline 5-year survival rate of patients diagnosed with stage I gastric cancer was expected to be 80%, compared with 60% in patients with stage II gastric cancer, and a 15% difference in survival would be a realistic expectation. Thus, a minimum of 276 patients were to be studied, providing 80% power to detect such a difference with <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec><sec id="Sec7"><title>Methods of Data Analysis</title><p id="Par14">Grouped data were expressed as median (range), and non-parametric methods were used throughout. Patient demographics were analyzed between the treatment modalities by means of <italic>&#x003c7;</italic>2 or non-parametric tests including Mann-Whitney <italic>U</italic> test. These tests were also employed in the analysis of disease recurrence and time to recurrence for the treatment groups. Overall survival was calculated from time of diagnosis to the date of death. This approach was adopted in previous randomized trials<xref ref-type="bibr" rid="CR8">8</xref> to allow for the variable interval to surgery following diagnosis, depending on whether neoadjuvant therapy was prescribed. Disease-free survival was measured from the date of surgery until the date of recurrence or date of censoring. The median follow-up was 60&#x000a0;months (range 6 to 60), with 273 patients (73%) followed up for 5&#x000a0;years or until death. No patients were lost to follow-up. Cumulative survival was calculated according to the method of Kaplan and Meier; differences between groups were analyzed with the log rank test. Univariable analyses examining factors influencing survival were examined initially by the life table method of Kaplan and Meier, and those with associations found to be significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.100) were retained in a Cox proportional hazards model using forward conditional methodology to assess the prognostic value of individual variables. All statistical analysis was performed in SPSS&#x000ae; (IBM&#x000ae; SPSS&#x000ae; Statistics v23.0.0.0, IBM Corporation, Armonk, New York, USA) with extension R.</p></sec></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Patients, Clinicopathological Factors, and Post-Operative Morbidity</title><p id="Par15">In total, 373 patients were identified who underwent surgery for gastric cancer. The complete baseline characteristics of all clinicopathological variables studied can be found in Table <xref rid="Tab1" ref-type="table">1</xref>. The median age for patients undergoing resection was 69&#x000a0;years (inter-quartile range (IQR) 55&#x02013;83) with the majority (43.7%) aged between 65 and 75&#x000a0;years. The majority of patients were male (68.1%), had distal cancers (43.7%), and were lymph node positive (55.2%). The median lymph node yield was 16 (range 3&#x02013;64) with an inter-quartile range of 13. Neoadjuvant chemotherapy was prescribed to 74 patients (19.8%), and 78 patients (20.9%) received post-operative adjuvant chemotherapy (Table <xref rid="Tab1" ref-type="table">1</xref>). There were 127 (34.0%) patients who developed post-operative complications, which were associated with 9 (2.4%) post-operative deaths within 90&#x000a0;days of surgery and 4 (1.1%) within 30&#x000a0;days of surgery. There were 74 (19.8%) infective and 22 (5.9%) non-infective complications (Table <xref rid="Tab2" ref-type="table">2</xref>). Post-operative complications were associated with proximal tumor location (<italic>p</italic>&#x000a0;=&#x02009;0.013), higher pN category (<italic>p</italic>&#x000a0;=&#x02009;0.016), higher pTNM stage (<italic>p</italic>&#x000a0;=&#x02009;0.038), vascular invasion (<italic>p</italic>&#x000a0;=&#x02009;0.008), higher R1 status (<italic>p</italic>&#x000a0;&#x0003c;&#x02009;0.001), but not neoadjuvant (<italic>p</italic>&#x000a0;=&#x02009;0.634) or adjuvant (<italic>p</italic>&#x000a0;=&#x02009;0.804) therapy (Table <xref rid="Tab3" ref-type="table">3</xref>). The median in-hospital length of stay (LOS) was 13&#x000a0;days (IQR 5&#x02013;21). The median in-hospital LOS for CDSC 0 was 11&#x000a0;days (IQR 7&#x02013;15), CDSC 1 was 16&#x000a0;days (IQR 8&#x02013;24), CDSC 2 was 17&#x000a0;days (IQR 9&#x02013;26), CDSC 3 was 24&#x000a0;days (IQR 10&#x02013;38), CDSC 4 was 26&#x000a0;days (IQR 0&#x02013;92), and CDSC 5 was 9&#x000a0;days (IQR 0&#x02013;35). During follow-up, 93 patients (24.9%) developed cancer recurrence and 150 patients (40.2%) died. Two hundred sixty-seven patients (71.6%) were followed up for 5&#x000a0;years or until death (median 60 (6&#x02013;60) months), and no patients were lost to follow-up.<table-wrap id="Tab1"><label>Table 1</label><caption><p>The relationship between tumor-related factors, overall survival, and disease-free survival in patients undergoing potentially curative resection for gastric cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Clinicopathological variables</th><th rowspan="2">Frequency n (%)</th><th>Disease-free survival</th><th rowspan="2"><italic>p</italic> value</th><th>Overall survival</th><th rowspan="2"><italic>p</italic> value</th></tr><tr><th>Five-year survival rate (%)</th><th>5&#x000a0;year survival rate (%)</th></tr></thead><tbody><tr><td colspan="6">Age (years)</td></tr><tr><td>&#x02009;&#x0003c;&#x02009;65<break/>&#x000a0;65&#x02013;75<break/>&#x02009;&#x0003e;&#x02009;75&#x000a0;years</td><td>125 (33.5)<break/>163 (43.7)<break/>85 (22.8)</td><td>50.0<break/>50.8<break/>60.7</td><td>0.371</td><td>51.1<break/>55.0<break/>60.7</td><td>0.507</td></tr><tr><td colspan="6">Sex</td></tr><tr><td>&#x000a0;Female<break/>&#x000a0;Male</td><td>119 (31.9)<break/>254 (68.1)</td><td>49.4<break/>54.3</td><td>0.446</td><td>53.9<break/>55.4</td><td>0.815</td></tr><tr><td colspan="6">Tumor site</td></tr><tr><td>&#x000a0;Proximal<break/>&#x000a0;Body<break/>&#x000a0;Distal</td><td>124 (33.2)<break/>86 (23.1)<break/>163 (43.7)</td><td>35.4<break/>65.7<break/>57.3</td><td>&#x0003c;&#x02009;0.001</td><td>39.0<break/>65.7<break/>59.7</td><td>0.002</td></tr><tr><td colspan="6">T category</td></tr><tr><td>&#x000a0;1<break/>&#x000a0;2<break/>&#x000a0;3<break/>&#x000a0;4</td><td>88 (23.6)<break/>28 (7.5)<break/>134 (35.9)<break/>123 (33.0)</td><td>83.8<break/>81.3<break/>48.8<break/>30.2</td><td>&#x0003c;&#x02009;0.001</td><td>83.8<break/>87.5<break/>50.5<break/>33.3</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td colspan="6">N category</td></tr><tr><td>&#x000a0;0<break/>&#x000a0;1<break/>&#x000a0;2<break/>&#x000a0;3</td><td>167 (44.8)<break/>76 (20.4)<break/>72 (19.3)<break/>58 (15.5)</td><td>73.1<break/>49.0<break/>31.3<break/>15.0</td><td>&#x0003c;&#x02009;0.001</td><td>74.6<break/>51.0<break/>33.3<break/>20.0</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td colspan="6">Tumor stage</td></tr><tr><td>&#x000a0;I<break/>&#x000a0;II<break/>&#x000a0;III</td><td>100 (26.8)<break/>119 (31.9)<break/>154 (41.3)</td><td>85.1<break/>58.1<break/>25.5</td><td>&#x0003c;&#x02009;0.001</td><td>85.1<break/>62.4<break/>27.4</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td colspan="6">Differentiation</td></tr><tr><td>&#x000a0;Well/moderate<break/>&#x000a0;Poor</td><td>188 (50.4)<break/>185 (49.6)</td><td>60.8<break/>43.8</td><td>0.005</td><td>62.9<break/>46.2</td><td>0.005</td></tr><tr><td colspan="6">Vascular invasion</td></tr><tr><td>&#x000a0;No<break/>&#x000a0;Yes</td><td>220 (59.0)<break/>153 (41.0)</td><td>64.8<break/>28.6</td><td>&#x0003c;&#x02009;0.001</td><td>66.5<break/>31.9</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td char="&#x000d7;" align="left" colspan="6">R status</td></tr><tr><td char="&#x000d7;" align="left">&#x000a0;0<break/>&#x000a0;1</td><td char="&#x000d7;" align="left">317 (85.0)<break/>56 (15.0)</td><td>61.2<break/>14.7</td><td char="&#x000d7;" align="left">&#x0003c;&#x02009;0.001</td><td>58.7<break/>14.7</td><td char="&#x000d7;" align="left">&#x0003c;&#x02009;0.001</td></tr><tr><td colspan="6">Neoadjuvant therapy</td></tr><tr><td>&#x000a0;No<break/>&#x000a0;Yes</td><td>299 (80.2)<break/>74 (19.8)</td><td>55.7<break/>37.2</td><td>0.026</td><td>57.8<break/>39.5</td><td>0.027</td></tr><tr><td colspan="6">Adjuvant therapy</td></tr><tr><td>&#x000a0;No<break/>&#x000a0;Yes</td><td>295 (79.1)<break/>78 (20.9)</td><td>54.9<break/>40.0</td><td>0.080</td><td>57.1<break/>42.5</td><td>0.087</td></tr><tr><td>Post-operative morbidity</td><td/><td/><td>&#x0003c;&#x02009;0.001</td><td/><td>0.001</td></tr><tr><td>&#x000a0;No<break/>&#x000a0;Yes</td><td>246 (66.0)<break/>127 (34.0)</td><td>59.5<break/>35.9</td><td/><td>61.5<break/>38.5</td><td/></tr><tr><td>Infective complication</td><td/><td/><td>0.167</td><td/><td>0.287</td></tr><tr><td>&#x000a0;No<break/>&#x000a0;Yes</td><td>299 (80.2)<break/>74 (19.8)</td><td>54.6<break/>43.5</td><td/><td>56.4<break/>47.8</td><td/></tr><tr><td>Non-infective complication</td><td/><td/><td>0.084</td><td/><td>0.060</td></tr><tr><td>&#x000a0;No<break/>&#x000a0;Yes</td><td>351 (94.1)<break/>22 (5.9)</td><td>53.8<break/>27.3</td><td/><td>56.1<break/>27.3</td><td/></tr><tr><td>Clavien-Dindo classification</td><td/><td/><td>0.007</td><td/><td>0.006</td></tr><tr><td>&#x000a0;0<break/>&#x000a0;1<break/>&#x000a0;2<break/>&#x000a0;3<break/>&#x000a0;4<break/>&#x000a0;5</td><td>246 (66.0)<break/>21 (5.6)<break/>57 (15.3)<break/>27 (7.2)<break/>13 (3.5)<break/>9 (2.4)</td><td>59.5<break/>42.9<break/>38.5<break/>37.5<break/>33.3<break/>0.00</td><td/><td>61.5<break/>42.9<break/>43.6<break/>37.5<break/>33.3<break/>0.0</td><td/></tr></tbody></table></table-wrap><table-wrap id="Tab2"><label>Table 2</label><caption><p>The incidence of complications in patients undergoing potentially curative resection for gastric cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Classification of complications</th></tr></thead><tbody><tr><td>Infective complications</td><td>74 (19.8%)</td></tr><tr><td colspan="2">Surgical site infection</td></tr><tr><td>&#x000a0;Anastomotic leak<break/>&#x000a0;Duodenal leak<break/>&#x000a0;Intra-abdominal abscess<break/>&#x000a0;Wound<break/>&#x000a0;Enterocutaneous fistula</td><td>18 (4.8%)<break/>5 (1.3%)<break/>3 (0.8%)<break/>18 (4.8%)<break/>2 (0.5%)</td></tr><tr><td colspan="2">Extra-abdominal infection</td></tr><tr><td>&#x000a0;Pneumonia<break/>&#x000a0;Urinary tract infection</td><td>24 (6.9%)<break/>3 (0.9%)</td></tr><tr><td>Non-infective complications</td><td>22 (5.9%)</td></tr><tr><td colspan="2">Cardiovascular</td></tr><tr><td>&#x000a0;Acute coronary syndrome<break/>&#x000a0;Atrial fibrillation</td><td>2 (0.5%)<break/>2 (0.5%)</td></tr><tr><td colspan="2">Respiratory</td></tr><tr><td>&#x000a0;Pulmonary embolus<break/>&#x000a0;Pulmonary edema<break/>&#x000a0;Pleural effusion</td><td>2 (0.5%)<break/>0 (0.0%)<break/>4 (1.1%)</td></tr><tr><td>Miscellaneous</td><td>12 (3.6%)</td></tr></tbody></table></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>The relationship between post-operative morbidity and clinicopathological factors in patients undergoing potentially curative resection for gastric cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Clinicopathological variables</th><th>No complication <italic>n</italic> (%)</th><th>Complication<italic>n</italic> (%)</th><th char="&#x000d7;"><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="4">Age (years)</td></tr><tr><td>&#x000a0;&#x0003c;&#x02009;65<break/>&#x000a0;65&#x02013;75<break/>&#x000a0;&#x0003e;&#x02009;75&#x000a0;years</td><td>87 (35.4)<break/>104 (42.3)<break/>55 (22.4)</td><td>37 (29.4)<break/>59 (46.8)<break/>30 (23.8)</td><td>0.504</td></tr><tr><td colspan="4">Sex</td></tr><tr><td>&#x000a0;Female<break/>&#x000a0;Male</td><td>76 (30.9)<break/>170 (69.1)</td><td>43 (34.1)<break/>83 (65.9)</td><td>0.527</td></tr><tr><td colspan="4">Tumor site</td></tr><tr><td>&#x000a0;Proximal<break/>&#x000a0;Body<break/>&#x000a0;Distal</td><td>71 (28.9)<break/>66 (26.8)<break/>109 (44.3)</td><td>53 (41.7)<break/>20 (15.7)<break/>54 (42.5)</td><td>0.013</td></tr><tr><td colspan="4">T category</td></tr><tr><td>&#x000a0;1<break/>&#x000a0;2<break/>&#x000a0;3<break/>&#x000a0;4</td><td>68 (27.6)<break/>16 (6.5)<break/>84 (34.1)<break/>78 (31.7)</td><td>21 (16.5)<break/>12 (9.4)<break/>49 (38.6)<break/>45 (35.4)</td><td>0.106</td></tr><tr><td colspan="4">N category</td></tr><tr><td>&#x000a0;0<break/>&#x000a0;1<break/>&#x000a0;2<break/>&#x000a0;3</td><td>125 (50.8)<break/>46 (18.7)<break/>40 (16.3)<break/>35 (14.2)</td><td>43 (33.9)<break/>29 (22.8)<break/>32 (25.2)<break/>23 (18.1)</td><td>0.016</td></tr><tr><td colspan="4">Tumor stage</td></tr><tr><td>&#x000a0;I<break/>&#x000a0;II<break/>&#x000a0;III</td><td>76 (30.9)<break/>78 (31.7)<break/>92 (37.4)</td><td>25 (19.7)<break/>40 (31.5)<break/>62 (48.8)</td><td>0.038</td></tr><tr><td colspan="4">Differentiation</td></tr><tr><td>&#x000a0;Well/moderate<break/>&#x000a0;Poor</td><td>124 (50.4)<break/>122 (49.6)</td><td>64 (50.4)<break/>63 (49.6)</td><td>0.998</td></tr><tr><td colspan="4">Vascular invasion</td></tr><tr><td>&#x000a0;No<break/>&#x000a0;Yes</td><td>157 (63.8)<break/>89 (36.3)</td><td>63 (49.6)<break/>64 (50.4)</td><td>0.008</td></tr><tr><td colspan="4">R status</td></tr><tr><td>&#x000a0;0<break/>&#x000a0;1</td><td>221 (89.8)<break/>25 (10.2)</td><td>96 (75.6)<break/>31 (24.4)</td><td>&#x0003c;0.001</td></tr><tr><td colspan="4">Neoadjuvant therapy</td></tr><tr><td>&#x000a0;No<break/>&#x000a0;Yes</td><td>196 (79.7)<break/>50 (20.3)</td><td>103 (81.7)<break/>23 (18.3)</td><td>0.634</td></tr><tr><td colspan="4">Adjuvant therapy</td></tr><tr><td>&#x000a0;No<break/>&#x000a0;Yes</td><td>196 (79.7)<break/>50 (20.3)</td><td>99 (78.6)<break/>27 (21.4)</td><td>0.804</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec10"><title>Relationships Between Post-Operative Complications and Disease-Free Survival</title><p id="Par16">A univariable analysis of factors associated with disease-free survival can be found in Table <xref rid="Tab4" ref-type="table">4</xref>. On multivariable analysis, pT category (hazard ratio (HR) 1.80 (95% confidence interval (CI) 1.35&#x02013;2.39, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), vascular invasion (HR 1.87 (1.17&#x02013;2.97), <italic>p</italic>&#x02009;=&#x02009;0.008), R1 status (HR 2.14 (1.32&#x02013;2.50), <italic>p</italic>&#x02009;=&#x02009;0.002), and post-operative complication (HR 1.63 (1.06&#x02013;2.50), <italic>p</italic>&#x02009;=&#x02009;0.026) were independently associated with disease-free survival (Table <xref rid="Tab4" ref-type="table">4</xref>). Five-year disease-free survival was 66.0% for patients without a complication compared with 34.0% for patients developing a post-operative complication (Table <xref rid="Tab1" ref-type="table">1</xref>, Fig <xref rid="Fig1" ref-type="fig">1</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Univariable and multivariable analysis of clinicopathological factors and complication markers: disease-free and overall survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"/><th>Univariable</th><th rowspan="3"><italic>p</italic> value</th><th>Multivariable</th><th rowspan="3"><italic>p</italic> value</th><th>Univariable</th><th rowspan="3"><italic>p</italic> value</th><th>Multivariable</th><th rowspan="3"><italic>p</italic> value</th></tr><tr><th>Disease-free survival</th><th/><th>Overall survival</th><th/></tr><tr><th>Hazard ratio (95% CI)</th><th>Hazard ratio (95% CI)</th><th>Hazard ratio (95% CI)</th><th>Hazard ratio (95% CI)</th></tr></thead><tbody><tr><td>Age (years)<break/>&#x0003c;&#x02009;65/66&#x02013;75/&#x0003e;&#x02009;75)</td><td>0.77 (0.57&#x02013;1.02)</td><td>0.072</td><td/><td/><td>0.89 (0.71&#x02013;1.11)</td><td>0.298</td><td/><td/></tr><tr><td>Gender<break/>(Female/male)</td><td>0.63 (0.41&#x02013;0.96)</td><td>0.031</td><td/><td>0.063</td><td>0.98 (0.69&#x02013;1.39)</td><td>0.894</td><td/><td/></tr><tr><td>Tumor site<break/>(Proximal/body/distal)</td><td>0.76 (0.59&#x02013;0.97)</td><td>0.028</td><td/><td>0.738</td><td>0.77 (0.63&#x02013;0.94)</td><td>0.009</td><td>0.79 (0.65&#x02013;0.96)</td><td>0.020</td></tr><tr><td>Neoadjuvant therapy<break/>(No/yes)</td><td>1.60 (0.99&#x02013;2.58)</td><td>0.053</td><td/><td/><td>1.40 (0.95&#x02013;2.07)</td><td>0.093</td><td/><td/></tr><tr><td colspan="9">Pathological factors</td></tr><tr><td>&#x000a0;T category<break/>(1/2/3/4)</td><td>2.19 (1.70&#x02013;2.82)</td><td>&#x0003c;&#x02009;0.001</td><td>1.80 (1.35&#x02013;2.39)</td><td>&#x0003c;&#x02009;0.001</td><td>1.93 (1.60&#x02013;2.32)</td><td>&#x0003c;&#x02009;0.001</td><td>1.67 (1.34&#x02013;2.06)</td><td>&#x0003c;&#x02009;0.001</td></tr><tr><td>&#x000a0;N category<break/>(0/1/2/3)</td><td>1.82 (1.52&#x02013;2.18)</td><td>&#x0003c;&#x02009;0.001</td><td/><td>0.081</td><td>1.66 (1.44&#x02013;1.92)</td><td>&#x0003c;&#x02009;0.001</td><td/><td>0.068</td></tr><tr><td>&#x000a0;TNM stage<break/>(I/II/III)</td><td>3.14 (2.24&#x02013;4.41)</td><td>&#x0003c;&#x02009;0.001</td><td/><td>0.574</td><td>2.49 (1.95&#x02013;3.18)</td><td>&#x0003c;&#x02009;0.001</td><td/><td>0.567</td></tr><tr><td>&#x000a0;Differentiation<break/>(Moderate/poor)</td><td>2.14 (1.39&#x02013;3.30)</td><td>0.001</td><td/><td>0.369</td><td>1.86 (1.33&#x02013;2.61)</td><td>&#x0003c;&#x02009;0.001</td><td/><td>0.089</td></tr><tr><td>&#x000a0;Vascular invasion<break/>(No/yes)</td><td>3.36 (2.19&#x02013;5.16)</td><td>&#x0003c;&#x02009;0.001</td><td>1.87 (1.17&#x02013;2.97)</td><td>0.008</td><td>2.96 (2.12&#x02013;4.15)</td><td>&#x0003c;&#x02009;0.001</td><td>1.76 (1.21&#x02013;2.55)</td><td>0.003</td></tr><tr><td>&#x000a0;R status<break/>(0/1)</td><td>4.19 (2.67&#x02013;6.58)</td><td>&#x0003c;&#x02009;0.001</td><td>2.14 (1.32&#x02013;3.45)</td><td>0.002</td><td>3.27 (2.25&#x02013;4.76)</td><td>&#x0003c;&#x02009;0.001</td><td/><td>0.619</td></tr><tr><td colspan="9">Post-operative factors</td></tr><tr><td>&#x000a0;Adjuvant therapy<break/>(No/yes)</td><td>1.56 (0.96&#x02013;2.53)</td><td>0.070</td><td/><td/><td>1.39 (0.93&#x02013;2.06)</td><td>0.105</td><td/><td/></tr><tr><td>&#x000a0;Post-operative morbidity<break/>(No/yes)</td><td>2.17 (1.42&#x02013;3.31)</td><td>&#x0003c;&#x02009;0.001</td><td>1.63 (1.06&#x02013;2.50)</td><td>0.026</td><td>2.28 (1.63&#x02013;3.17)</td><td>&#x0003c;&#x02009;0.001</td><td>2.25 (1.04&#x02013;4.85)</td><td>0.039</td></tr><tr><td>&#x000a0;Infective complication<break/>(No/yes)</td><td>1.30 (0.77&#x02013;2.18)</td><td>0.328</td><td/><td/><td>1.42 (0.95&#x02013;2.12)</td><td>0.084</td><td/><td/></tr><tr><td>&#x000a0;Non-infective complication<break/>(No/yes)</td><td>2.06 (0.90&#x02013;4.72)</td><td>0.089</td><td/><td/><td>3.54 (2.03&#x02013;6.17)</td><td>&#x0003c;&#x02009;0.001</td><td/><td>0.061</td></tr><tr><td>&#x000a0;Clavien-Dindo classification<break/>(0/1/2/3/4/5)</td><td>1.27 (1.08&#x02013;1.50)</td><td>0.004</td><td/><td>0.197</td><td>1.50 (1.33&#x02013;1.79)</td><td>&#x0003c;&#x02009;0.001</td><td>1.76 (1.35&#x02013;2.29)</td><td>&#x0003c;&#x02009;0.001</td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>The relationship between post-operative complication, disease-free <bold>a</bold>, and overall survival&#x000a0;<bold>b</bold></p></caption><graphic xlink:href="11605_2018_3787_Fig1_HTML" id="MO1"/></fig></p><p id="Par17">Patients were stratified into pTNM stage I and II, or pTNM stage III disease. Post-operative complication was associated with poorer disease-free survival (<italic>p</italic>&#x02009;=&#x02009;0.038, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a) in TNM stage I and II disease, but not in stage III disease (<italic>p</italic>&#x02009;=&#x02009;0.158, Fig. <xref rid="Fig2" ref-type="fig">2</xref>c). On multivariable analysis, post-operative complication was not independently associated with poorer disease-free survival when confounded for other statistically significant factors (Tables&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> and <xref rid="Tab6" ref-type="table">6</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>The relationship between post-operative complication, disease-free, and overall survival in patients with stage I and II gastric cancer. <bold>a</bold> Disease-free survival in patients with TNM stage I and II gastric cancer. <bold>b</bold> Overall survival in patients with TNM stage I and II gastric cancer. <bold>c</bold> Disease-free survival in patients with TNM stage III gastric cancer. <bold>d</bold> Overall survival in patients with TNM stage III gastric cancer</p></caption><graphic xlink:href="11605_2018_3787_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab5"><label>Table 5</label><caption><p>Clinicopathological factors and survival in stage I and II gastric cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"/><th>Univariable</th><th rowspan="3"><italic>p</italic> value</th><th>Multivariable</th><th rowspan="3"><italic>p</italic> value</th><th>Univariable</th><th rowspan="3"><italic>p</italic> value</th><th>Multivariable</th><th rowspan="3"><italic>p</italic> value</th></tr><tr><th>Disease-free survival</th><th/><th>Overall survival</th><th/></tr><tr><th>Hazard ratio (95% CI)</th><th>Hazard ratio (95% CI)</th><th>Hazard ratio (95% CI)</th><th>Hazard ratio (95% CI)</th></tr></thead><tbody><tr><td>Age (years)<break/>&#x0003c;&#x02009;65/66&#x02013;75/&#x0003e;&#x02009;75)</td><td>0.72 (0.44&#x02013;1.17)</td><td>0.186</td><td/><td/><td>1.09 (0.76&#x02013;1.56)</td><td>0.648</td><td/><td/></tr><tr><td>Gender<break/>(Female/male)</td><td>0.99 (0.47&#x02013;2.10)</td><td>0.981</td><td/><td/><td>1.21 (0.66&#x02013;2.19)</td><td>0.540</td><td/><td/></tr><tr><td>Tumor site<break/>(Proximal/body/distal)</td><td>0.61 (0.40&#x02013;0.93)</td><td>0.022</td><td/><td>0.231</td><td>0.67 (0.49&#x02013;0.92)</td><td>0.013</td><td>0.68 (0.50&#x02013;0.93)</td><td>0.014</td></tr><tr><td>Neoadjuvant therapy<break/>(No/yes)</td><td>2.29 (1.05&#x02013;5.00)</td><td>0.037</td><td/><td>0.662</td><td>1.92 (1.04&#x02013;3.54)</td><td>0.037</td><td/><td>0.961</td></tr><tr><td colspan="9">Pathological factors</td></tr><tr><td>&#x000a0;T category<break/>(1/2/3/4)</td><td>1.89 (1.34&#x02013;2.65)</td><td>&#x0003c;&#x02009;0.001</td><td/><td>0.845</td><td>1.48 (1.16&#x02013;1.89)</td><td>0.001</td><td/><td>0.902</td></tr><tr><td>&#x000a0;N category<break/>(0/1/2/3)</td><td>2.92 (1.74&#x02013;4.92)</td><td>&#x0003c;&#x02009;0.001</td><td/><td>0.310</td><td>1.64 (1.02&#x02013;2.62)</td><td>0.039</td><td/><td>0.711</td></tr><tr><td>&#x000a0;TNM stage<break/>(I/II)</td><td>14.28 (3.41&#x02013;59.85)</td><td>&#x0003c;&#x02009;0.001</td><td>10.13 (2.37&#x02013;43.31)</td><td>0.002</td><td>3.28 (1.73&#x02013;6.23)</td><td>&#x0003c;&#x02009;0.001</td><td>2.94 (1.51&#x02013;5.74)</td><td>0.002</td></tr><tr><td>&#x000a0;Differentiation<break/>(Moderate/poor)</td><td>1.47 (0.72&#x02013;2.96)</td><td>0.288</td><td/><td/><td>1.07 (0.62&#x02013;1.84)</td><td>0.814</td><td/><td/></tr><tr><td>&#x000a0;Vascular invasion<break/>(No/yes)</td><td>4.23 (2.08&#x02013;8.58)</td><td>&#x0003c;&#x02009;0.001</td><td>2.66 (1.26&#x02013;5.59)</td><td>0.010</td><td>3.23 (1.88&#x02013;5.56)</td><td>&#x0003c;&#x02009;0.001</td><td>2.33 (1.29&#x02013;4.20)</td><td>0.005</td></tr><tr><td>&#x000a0;R status<break/>(0/1)</td><td>10.56 (4.65&#x02013;23.96)</td><td>&#x0003c;&#x02009;0.001</td><td>4.18 (1.76&#x02013;9.93)</td><td>0.001</td><td>4.42 (2.06&#x02013;9.46)</td><td>&#x0003c;&#x02009;0.001</td><td/><td>0.536</td></tr><tr><td colspan="9">Post-operative factors</td></tr><tr><td>&#x000a0;Adjuvant therapy<break/>(No/yes)</td><td>1.80 (0.78&#x02013;4.20)</td><td>0.172</td><td/><td/><td>1.75 (0.92&#x02013;3.24)</td><td>0.090</td><td/><td/></tr><tr><td>&#x000a0;Post-operative morbidity<break/>(No/yes)</td><td>2.15 (1.04&#x02013;4.43)</td><td>0.038</td><td/><td>0.474</td><td>2.43 (1.42&#x02013;4.18)</td><td>0.001</td><td>7.06 (1.89&#x02013;26.38)</td><td>0.004</td></tr><tr><td>&#x000a0;Infective complication<break/>(No/yes)</td><td>1.57 (0.67&#x02013;3.63)</td><td>0.297</td><td/><td/><td>1.84 (1.00&#x02013;3.38)</td><td>0.051</td><td/><td/></tr><tr><td>&#x000a0;Non-infective complication<break/>(No/yes)</td><td>1.43 (0.19&#x02013;10.51)</td><td>0.727</td><td/><td/><td>3.20 (1.15&#x02013;8.91)</td><td>0.026</td><td/><td>0.864</td></tr><tr><td>&#x000a0;Clavien-Dindo classification<break/>(0/1/2/3/4/5)</td><td>1.26 (0.93&#x02013;1.70)</td><td>0.142</td><td/><td/><td>1.66 (1.37&#x02013;2.00)</td><td>&#x0003c;&#x02009;0.001</td><td>2.93 (1.89&#x02013;4.55)</td><td>&#x0003c;&#x02009;0.001</td></tr></tbody></table></table-wrap><table-wrap id="Tab6"><label>Table 6</label><caption><p>Clinicopathological factors and survival in stage III gastric cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"/><th>Univariable</th><th rowspan="3"><italic>p</italic> value</th><th>Multivariable</th><th rowspan="3"><italic>p</italic> value</th><th>Univariable</th><th rowspan="3"><italic>p</italic> value</th><th>Multivariable</th><th rowspan="3"><italic>p</italic> value</th></tr><tr><th>Disease-free survival</th><th/><th>Overall survival</th><th/></tr><tr><th>Hazard ratio (95% CI)</th><th>Hazard ratio (95% CI)</th><th>Hazard ratio (95% CI)</th><th>Hazard ratio (95% CI)</th></tr></thead><tbody><tr><td>Age (years)<break/>&#x0003c;&#x02009;65/66&#x02013;75/&#x0003e;&#x02009;75)</td><td>0.85 (0.60&#x02013;1.21)</td><td>0.374</td><td/><td/><td>0.86 (0.65&#x02013;1.15)</td><td>0.302</td><td/><td/></tr><tr><td>Gender<break/>(Female/male)</td><td>0.44 (0.27&#x02013;0.72)</td><td>0.001</td><td>0.44 (0.26&#x02013;0.72)</td><td>0.001</td><td>0.82 (0.54&#x02013;1.24)</td><td>0.350</td><td/><td/></tr><tr><td>Tumor site<break/>(Proximal/body/distal)</td><td>0.92 (0.69&#x02013;1.23)</td><td>0.583</td><td/><td/><td>0.97 (0.77&#x02013;1.23)</td><td>0.801</td><td/><td/></tr><tr><td>Neoadjuvant therapy<break/>(No/yes)</td><td>1.13 (0.63&#x02013;2.02)</td><td>0.683</td><td/><td/><td>0.94 (0.58&#x02013;1.54)</td><td>0.814</td><td/><td/></tr><tr><td colspan="9">Pathological factors</td></tr><tr><td>&#x000a0;T category<break/>(1/2/3/4)</td><td>1.58 (0.92&#x02013;2.71)</td><td>0.097</td><td/><td/><td>1.63 (1.06&#x02013;2.53)</td><td>0.028</td><td/><td/></tr><tr><td>&#x000a0;N category<break/>(0/1/2/3)</td><td>1.26 (0.88&#x02013;1.80)</td><td>0.202</td><td/><td/><td>1.30 (0.97&#x02013;1.73)</td><td>0.079</td><td/><td>0.051</td></tr><tr><td>&#x000a0;Differentiation<break/>(Moderate/poor)</td><td>1.82 (1.06&#x02013;3.13)</td><td>0.031</td><td>1.91 (1.11&#x02013;3.30)</td><td>0.020</td><td>1.87 (1.20&#x02013;2.91)</td><td>0.006</td><td>1.80 (1.15&#x02013;2.84)</td><td>0.011</td></tr><tr><td>&#x000a0;Vascular invasion<break/>(No/yes)</td><td>1.79 (1.05&#x02013;3.07)</td><td>0.033</td><td>1.84 (1.07&#x02013;3.15)</td><td>0.027</td><td>1.55 (1.02&#x02013;2.37)</td><td>0.041</td><td/><td>0.063</td></tr><tr><td>&#x000a0;R status<break/>(0/1)</td><td>1.64 (0.96&#x02013;2.78)</td><td>0.069</td><td/><td/><td>1.61 (1.05&#x02013;2.47)</td><td>0.031</td><td/><td>0.328</td></tr><tr><td colspan="9">Post-operative factors</td></tr><tr><td>&#x000a0;Adjuvant therapy<break/>(No/yes)</td><td>1.13 (0.64&#x02013;2.00)</td><td>0.676</td><td/><td/><td>0.95 (0.59&#x02013;1.54)</td><td>0.844</td><td/><td/></tr><tr><td>&#x000a0;Post-operative morbidity<break/>(No/yes)</td><td>1.44 (0.87&#x02013;2.38)</td><td>0.158</td><td/><td/><td>1.74 (1.16&#x02013;2.60)</td><td>0.007</td><td/><td>0.770</td></tr><tr><td>&#x000a0;Infective complication<break/>(No/yes)</td><td>0.99 (0.52&#x02013;1.91)</td><td>0.982</td><td/><td/><td>1.14 (0.69&#x02013;1.89)</td><td>0.606</td><td/><td/></tr><tr><td>&#x000a0;Non-infective complication<break/>(No/yes)</td><td>1.44 (0.58&#x02013;3.61)</td><td>0.432</td><td/><td/><td>2.74 (1.41&#x02013;5.29)</td><td>0.003</td><td>2.24 (1.10&#x02013;4.53)</td><td>0.025</td></tr><tr><td>&#x000a0;Clavien-Dindo classification<break/>(0/1/2/3/4/5)</td><td>1.10 (0.90&#x02013;1.35)</td><td>0.338</td><td/><td/><td>1.28 (1.10&#x02013;1.49)</td><td>0.001</td><td>1.21 (1.04&#x02013;1.42)</td><td>0.015</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec11"><title>Relationship Between Post-Operative Complications and Overall Survival</title><p id="Par18">A univariable analysis of factors associated with overall survival can be found in Table <xref rid="Tab4" ref-type="table">4</xref>. On multivariable analysis only pT category (HR 1.67 (1.34&#x02013;2.06), <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), vascular invasion (HR 1.76 (1.21&#x02013;2.55), <italic>p</italic>&#x02009;=&#x02009;0.003), post-operative complication (HR 2.25 (1.04&#x02013;4.85), <italic>p</italic>&#x02009;=&#x02009;0.039), and Clavien-Dindo classification (HR 1.76 (1.35&#x02013;2.29), <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) were independently associated with poor overall survival (Table <xref rid="Tab4" ref-type="table">4</xref>).</p><p id="Par19">Patients were stratified into TNM stage I and II, or TNM stage III disease. Post-operative complication was associated with poorer overall survival in TNM stage I and II disease (<italic>p</italic>&#x02009;=&#x02009;0.001, Fig. <xref rid="Fig2" ref-type="fig">2</xref>b) and stage III disease (<italic>p</italic>&#x02009;=&#x02009;0.007, Fig. <xref rid="Fig2" ref-type="fig">2</xref>d). On multivariable analysis, post-operative complication was only independently associated with poorer overall survival in patients with stage I and II disease (HR 7.06 (1.89&#x02013;26.38), <italic>p</italic>&#x02009;=&#x02009;0.004) (Table <xref rid="Tab5" ref-type="table">5</xref>). Non-infective complications were associated with poorer overall survival in stage III disease (HR 2.24 (1.10&#x02013;4.53), <italic>p</italic>&#x02009;=&#x02009;0.025) (Table <xref rid="Tab5" ref-type="table">5</xref>). Clavien-Dindo classification was also independently associated with poor overall survival in stage I and II disease (HR 2.93 (1.89&#x02013;4.55); <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and stage III disease (HR 1.21 (1.04&#x02013;1.42); <italic>p</italic>&#x02009;=&#x02009;0.015) (Table <xref rid="Tab6" ref-type="table">6</xref>).</p></sec></sec><sec id="Sec12"><title>Discussion</title><p id="Par20">Surgical outcomes, in broad terms, have never been better or more transparent, despite the contemporary challenges of an increasingly elderly, comorbid, and sometimes frail population. High-risk surgical patients are at greater danger of post-operative complications, prolonged durations of hospital stay, and recovery in general blighted by a compromised quality of life. Moreover, patients diagnosed with cancer face and pose specific problems, including debility, weight loss, malnutrition, and anemia that may all impact outcomes. This is the first study to highlight the prognostic significance of post-operative morbidity severity classification after D2 gastrectomy for carcinoma. The principal findings supported the working hypothesis and showed that the one third of the patients who suffered any complication were 40% less likely to enjoy disease-free 5-year survival. The poorer survival associated with post-operative complications was independent of tumor histopathological stage, suggesting that treatment strategies aimed at minimizing complications may not only improve oncological outcome but also reduce lengths of hospital stay, improve quality of life, with allied consequent economic benefits for hospital services and prudent NHS health care.</p><p id="Par21">Patients carrying significant comorbidities, poor functional performance, and higher risk assessment profiles are well recognized to suffer poorer post-operative quality of life and cumulative survival following abdominal surgery.<xref ref-type="bibr" rid="CR12">12</xref> Yet, only recently have the associations between pre-operative physiological functional status and post-operative disease recurrence been appreciated.<xref ref-type="bibr" rid="CR2">2</xref> Richards et al. reported in a cohort of patients from Glasgow, Scotland, with pTNM stage I&#x02013;III colorectal cancer that poor pre-operative POSSUM scores were 50%more likely to develop post-operative complications and disease recurrence.<xref ref-type="bibr" rid="CR2">2</xref> Similarly, Kang et al. (South Korea),<xref ref-type="bibr" rid="CR13">13</xref> Zhang et al. (China), and <xref ref-type="bibr" rid="CR14">14</xref> Inokuchi (Tokyo)<xref ref-type="bibr" rid="CR15">15</xref> have reported an association between pre-operative serum albumin and surgical complications in patients undergoing gastrectomy for cancer, which suggest that the systemic inflammatory response plays a pivotal role. Unfortunately, these latter reports focused only on serum albumin analyses and, other SIR biomarkers such as the C-reactive protein-based modified Glasgow Prognostic Score, may provide better prognostic information. Indeed, in a recent report comparing a raft of all serum-based inflammatory biomarkers, the modified Glasgow Prognostic Score (mGPS) was the only inflammatory marker independently associated with disease recurrence and overall survival.<xref ref-type="bibr" rid="CR16">16</xref> Measures that optimize the patients&#x02019; risk assessment profiles may offer the greatest therapeutic benefit, and the magnitude of these benefits has been signaled in a recent report form Barberan-Garcia et al. (Barcelona) who observed a 51% reduction in post-operative morbidity in patients undergoing intensive prehabilitation programs prior to major abdominal surgery.<xref ref-type="bibr" rid="CR17">17</xref></p><p id="Par22">The adverse influence of global post-operative morbidity on overall survival has been reported previously. Li et al. from China<xref ref-type="bibr" rid="CR1">1</xref> reported significantly poorer 5-year overall survival in a cohort of 432 patients when morbidity occurred (21.8%) compared with controls (39.9%), which was independent of confounding factors (HR 2.5. <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). However, the value of overall survival as an outcome measure is relatively limited because of the inclusion of non-cancer-related deaths in the analysis, diluting the prognostic influence of cancer biology. In contrast, septic complications after surgery have been implicated in influencing disease-free survival.<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref> Both Tokunga et al.<xref ref-type="bibr" rid="CR18">18</xref> (<italic>n</italic>&#x02009;=&#x02009;756) and Hayashi et al.<xref ref-type="bibr" rid="CR19">19</xref> (Japan) (<italic>n</italic>&#x02009;=&#x02009;502) contended that sepsis was associated with poorer disease-free 5-year survival of the order of 20% (HR 2.22, <italic>p</italic>&#x02009;=&#x02009;0.002) and 25% (HR 1.96, <italic>p</italic>&#x02009;=&#x02009;0.013), respectively. The findings of this study are not in keeping with the above, but are in line with those reported by Nelen et from the Netherlands<xref ref-type="bibr" rid="CR20">20</xref> with sepsis associated with 33.1% poorer disease-free 5-year survival. Moreover, respiratory sepsis was fourfold greater in western cohorts (20%)<xref ref-type="bibr" rid="CR20">20</xref> when compared with eastern cohorts (5%).<xref ref-type="bibr" rid="CR19">19</xref></p><p id="Par23">There are a number of inherent limitations and potential criticisms of this study. Data related to the patients&#x02019; race, body mass indices, and detailed comorbidity was not collected prospectively and was therefore not available for analysis as confounding factors. The patient cohort studied is a selected group (most had undergone a potentially curative R0 gastrectomy) and was not representative of all gastric cancer patients; indeed, only approximately one third of the South Wales patients undergo potentially curative resection.<xref ref-type="bibr" rid="CR21">21</xref> In contrast, the study has several strengths, benefiting from robust follow-up data with accurate causes and dates of death obtained from the office of national statistics; over 75% were followed up for at least 5&#x000a0;years or death. Patients were recruited consecutively from a single UK geographical region, and all had been treated by the same multidisciplinary team and group of specialist surgeons, using a standardized staging algorithm and operative technique, with extensive audited and published quality control. Moreover, the findings cannot be criticized because of poor surgical outcomes, which compare favorably with national trial and audit data in terms of post-operative morbidity and cumulative survival.<xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR6">6</xref></p><p id="Par24">In conclusion, the concept of surgical prehabilitation refers to an emerging field of research concerned with strategies to optimize the patients&#x02019; preoperative physical and psychosocial risk profiles, such that post-operative recovery trajectories are boosted, resulting in fewer complications, shorter durations of hospital stay, improved quality of life, and cost-effective prudent health care. Reports to date have focused on a heterogenous group of health interventions, applied within the care continuum, and occurring between the diagnosis and the start of surgical treatment. These have included, education, exercise, nutrition, and psychosocial approaches, focused not only the patient but also the patient&#x02019;s family, with the aim of promoting health-related behavioral change that reaches beyond the immediate preoperative period into the future and longer term. Prehabilitation is the logical precursor to enhanced recovery programmes but should comprise more than just exercise. Nutritional and psychosocial well-being are also critical aspects of perioperative care and key components of prehabilitation programs. The preoperative period presents an opportunity to utilize a so-called &#x0201c;teachable moment&#x0201d; and emphasize the importance of positive lifestyle change such as smoking cessation. Future research efforts should explore combining and fusing prehabilitation with enhanced recovery programmes to catalyze additional improvements in outcomes. Moreover, cost-effectiveness evaluation should form part of future research. Prehabilitation in specialties with high-risk profiles will probably be associated with additional costs, though it is possible, if not likely, that such costs would be offset by improved outcomes such as shorter durations of hospital stay, fewer complications, and better quality of life. Finally and by tradition, prehabilitation programs are prescriptive and generic: employing a one size fits all philosophy. Bespoke personalized programs, related to the individual patients&#x02019; physiological, functional, psychosocial profiles, and including combinations of supervised and independent self-assessed exercises, delivered in the community rather than secondary care are likely to be associated with greater compliance and effect.</p></sec><sec sec-type="supplementary-material"><title>Electronic Supplementary Material</title><sec id="Sec13"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11605_2018_3787_MOESM1_ESM.docx"><label>ESM 1</label><caption><p>(DOCX 246kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><notes notes-type="author-contribution"><title>Author Declaration</title><p>AP<bold>&#x02014;c</bold>onceived and designed study, collected data, analyzed data<bold>,</bold> and prepared manuscript. Agreed on final draft for submission.</p><p>AC<bold>&#x02014;c</bold>ollected data, helped interpret results, drafted manuscripts<bold>,</bold> and agreed on final draft.</p><p>NP<bold>&#x02014;c</bold>ollected data, helped with data analysis, drafted manuscript<bold>,</bold> and agreed on final draft.</p><p>DC<bold>&#x02014;c</bold>ollected data, helped with data analysis, drafted manuscript<bold>,</bold> and agreed on final draft.</p><p>AC<bold>&#x02014;h</bold>elped design study and interpret results. Drafted manuscript and agreed on final draft.</p><p>WL<bold>&#x02014;h</bold>elped conceive and design the study. Helped with data analysis and preparation of manuscript. Agreed on final draft.</p></notes><notes notes-type="COI-statement"><title>Compliance with Ethical Standards</title><sec id="FPar1"><title>Conflict of Interest</title><p>The authors declare that they have no conflict of interest.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q-G</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Tang</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>D-R</given-names></name></person-group><article-title>Impact of postoperative complications on long-term survival after radical resection for gastric cancer</article-title><source>World Journal of Gastroenterology</source><year>2013</year><volume>19</volume><fpage>4060</fpage><lpage>4065</lpage><pub-id pub-id-type="doi">10.3748/wjg.v19.i25.4060</pub-id><pub-id pub-id-type="pmid">23840153</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>CH</given-names></name><name><surname>Platt</surname><given-names>JJ</given-names></name><name><surname>Anderson</surname><given-names>JH</given-names></name><name><surname>McKee</surname><given-names>RF</given-names></name><name><surname>Horgan</surname><given-names>PG</given-names></name><name><surname>McMillan</surname><given-names>DC</given-names></name></person-group><article-title>The impact of perioperative risk, tumor pathology and surgical complications on disease recurrence following potentially curative resection of colorectal cancer</article-title><source>Ann Surg</source><year>2011</year><volume>254</volume><fpage>83</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/SLA.0b013e31821fd469</pub-id><pub-id pub-id-type="pmid">21572320</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Andreou A, Bieb lM, Dadras M, Struecker B, Sauer IM Thuss-Patience PC, Chopra S, Fikatas P, Bahra M, Seehofer D, Pratschke J, Schmidt SC. Anastomotic leak predicts diminished long-term survival after resection for gastric and esophageal cancer. <italic>Surgery</italic> 2016; <bold>160</bold>: 191&#x02013;203. 10.1016/j.surg.2016.02.020.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>HR</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Parkin</surname><given-names>DM</given-names></name></person-group><article-title>Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</article-title><source>Int J Cancer</source><year>2010</year><volume>127</volume><fpage>2893</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1002/ijc.25516</pub-id><pub-id pub-id-type="pmid">21351269</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">National Oesophago-Gastric Cancer Audit Progress Report 2014 (NOGCA 2014) An Audit of the care received by people with Oesophago-Gastric Cancer in England and Wales<italic>.</italic> 2014. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.augis.org/wp-content/uploads/2014/05/NOGCA-PROGRESS-Report-2014_Final.V2.pdf">http://www.augis.org/wp-content/uploads/2014/05/NOGCA-PROGRESS-Report-2014_Final.V2.pdf</ext-link> [Accessed 27th October 2017].</mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">National Oesophago-Gastric Cancer Audit Progress Report 2016 (NOGCA 2016) An Audit of the care received by people with Oesophago-Gastric Cancer in England and Wales<italic>.</italic> 2016. Available from: <ext-link ext-link-type="uri" xlink:href="https://digital.nhs.uk/catalogue/PUB21561">https://digital.nhs.uk/catalogue/PUB21561</ext-link>[Accessed 27th October 2017].</mixed-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Angelica</surname><given-names>M</given-names></name><name><surname>Gonen</surname><given-names>M</given-names></name><name><surname>Brennan</surname><given-names>MF</given-names></name><name><surname>Turnbull</surname><given-names>AD</given-names></name><name><surname>Bains</surname><given-names>M</given-names></name><name><surname>Karpeh</surname><given-names>MS</given-names></name></person-group><article-title>Patterns of Initial Recurrence in Completely Resected Gastric Adenocarcinoma</article-title><source>Ann Surg</source><year>2004</year><volume>240</volume><fpage>808</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000143245.28656.15</pub-id><pub-id pub-id-type="pmid">15492562</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Allum</surname><given-names>WH</given-names></name><name><surname>Stenning</surname><given-names>SP</given-names></name><name><surname>Thompson</surname><given-names>JN</given-names></name><name><surname>Van de Velde</surname><given-names>CJ</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Scarffe</surname><given-names>JH</given-names></name><name><surname>Lofts</surname><given-names>FJ</given-names></name><name><surname>Falk</surname><given-names>SJ</given-names></name><name><surname>Iveson</surname><given-names>TJ</given-names></name><name><surname>Smith</surname><given-names>DB</given-names></name><name><surname>Langley</surname><given-names>RE</given-names></name><name><surname>Verma</surname><given-names>M</given-names></name><name><surname>Weeden</surname><given-names>S</given-names></name><name><surname>Chua</surname><given-names>YJ</given-names></name><name><surname>Trial Participants</surname><given-names>MAGIC</given-names></name></person-group><article-title>Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa055531</pub-id><pub-id pub-id-type="pmid">16822992</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karran</surname><given-names>A</given-names></name><name><surname>Wheat</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>D</given-names></name><name><surname>Blake</surname><given-names>P</given-names></name><name><surname>Barlow</surname><given-names>R</given-names></name><name><surname>Lewis</surname><given-names>WG</given-names></name></person-group><article-title>Propensity Score Analysis of an Enhanced Recovery Programme in Upper Gastrointestinal Cancer Surgery</article-title><source>World J Surg</source><year>2016</year><volume>40</volume><fpage>1645</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1007/s00268-016-3473-6</pub-id><pub-id pub-id-type="pmid">26956905</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edge</surname><given-names>SB</given-names></name><name><surname>Compton</surname><given-names>CC</given-names></name></person-group><article-title>The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM</article-title><source>Ann Surg Oncol</source><year>2010</year><volume>17</volume><fpage>1471</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1245/s10434-010-0985-4</pub-id><pub-id pub-id-type="pmid">20180029</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dindo</surname><given-names>D</given-names></name><name><surname>Demartines</surname><given-names>N</given-names></name><name><surname>Clavien</surname><given-names>PA</given-names></name></person-group><article-title>Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey</article-title><source>Ann Surg</source><year>2004</year><volume>240</volume><fpage>205</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1097/01.sla.0000133083.54934.ae</pub-id><pub-id pub-id-type="pmid">15273542</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>N</given-names></name><name><surname>Wada</surname><given-names>J</given-names></name><name><surname>Niki</surname><given-names>M</given-names></name><name><surname>Sugiyama</surname><given-names>Y</given-names></name><name><surname>Mushiake</surname><given-names>H</given-names></name></person-group><article-title>Factors predicting mortality in emergency abdominal surgery in the elderly</article-title><source>World J Emerg Surg</source><year>2012</year><volume>7</volume><fpage>12</fpage><pub-id pub-id-type="doi">10.1186/1749-7922-7-12</pub-id><pub-id pub-id-type="pmid">22578159</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>SC</given-names></name><name><surname>Kim</surname><given-names>HI</given-names></name><name><surname>Kim</surname><given-names>MG</given-names></name></person-group><article-title>Low Serum Albumin Level, Male Sex, and Total Gastrectomy Are Risk Factors of Severe Postoperative Complications in Elderly Gastric Cancer Patients</article-title><source>J Gastric Cancer</source><year>2016</year><volume>16</volume><fpage>43</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.5230/jgc.2016.16.1.43</pub-id><pub-id pub-id-type="pmid">27104026</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>WH</given-names></name><name><surname>Chen</surname><given-names>XZ</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>DJ</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>ZX</given-names></name><name><surname>Chen</surname><given-names>JP</given-names></name><name><surname>Zhou</surname><given-names>ZG</given-names></name><name><surname>Hu</surname><given-names>JK</given-names></name></person-group><article-title>Risk Factors and Survival Outcomes for Postoperative Pulmonary Complications in Gastric Cancer Patients</article-title><source>Hepatogastroenterology</source><year>2015</year><volume>62</volume><fpage>766</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">26897970</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Inokuchi M, Kojima K, Kato K, Sugita H, Sugihara K. Risk factors for post-operative pulmonary complications after gastrectomy for gastric cancer. <italic>Surg Infect</italic> (Larchmt) 2014; <bold>15</bold>: 314&#x02013;21. 10.1089/sur.2013.031.</mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Powell AG, Parkinson D, Pate lN, Christian A, Lewis WG. Prognostic significance of serum inflammatory markers in gastric cancer. <italic>J Gastrointest Surg</italic>. 2017 <bold>[In Press]</bold>.</mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Barberan-Garcia A, Ubr&#x000e9;M, Roca J, Lacy AM, Burgos F, Risco R, Mombl&#x000e1;n D, Balust J, Blanco I, Mart&#x000ed;nez-Pall&#x000ed; G. Personalised Prehabilitation in High-risk Patients Undergoing Elective Major Abdominal Surgery: A Randomized Blinded Controlled Trial. <italic>Ann Surg</italic> 2017; May 9. 10.1097/SLA.0000000000002293.</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tokunaga</surname><given-names>M</given-names></name><name><surname>Tanizawa</surname><given-names>Y</given-names></name><name><surname>Bando</surname><given-names>E</given-names></name><name><surname>Kawamura</surname><given-names>T</given-names></name><name><surname>Terashima</surname><given-names>M</given-names></name></person-group><article-title>Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer</article-title><source>Ann Surg Oncol</source><year>2013</year><volume>20</volume><fpage>1575</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1245/s10434-012-2720-9</pub-id><pub-id pub-id-type="pmid">23076557</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Aoyama</surname><given-names>T</given-names></name><name><surname>Hasegawa</surname><given-names>S</given-names></name><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Tsuchida</surname><given-names>K</given-names></name><name><surname>Fujikawa</surname><given-names>H</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Ogata</surname><given-names>T</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Oshima</surname><given-names>T</given-names></name><name><surname>Rino</surname><given-names>Y</given-names></name><name><surname>Masuda</surname><given-names>M</given-names></name></person-group><article-title>Impact of infectious complications on gastric cancer recurrence</article-title><source>Gastric Cancer</source><year>2015</year><volume>18</volume><fpage>368</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1007/s10120-014-0361-3</pub-id><pub-id pub-id-type="pmid">24634097</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Nelen SD, Heuthorst L, Verhoeven RHA, Polat F, Kruyt PM, Reijnders K, Ferenschild FTJ, Bonenkamp JJ, Rutter JE, deWilt JHW, Spillenaar Bilgen EJ. Impact of Centralizing Gastric Cancer Surgery on Treatment, Morbidity, and Mortality. <italic>J Gastrointest Surg</italic> 2017 Aug 16. 10.1007/s11605-017-3531-x.</mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>DS</given-names></name><name><surname>Reid</surname><given-names>TD</given-names></name><name><surname>White</surname><given-names>C</given-names></name><name><surname>Willicombe</surname><given-names>A</given-names></name><name><surname>Blackshaw</surname><given-names>G</given-names></name><name><surname>Clark</surname><given-names>GW</given-names></name><name><surname>Havard</surname><given-names>TJ</given-names></name><name><surname>Escofet</surname><given-names>X</given-names></name><name><surname>Crosby</surname><given-names>TD</given-names></name><name><surname>Roberts</surname><given-names>SA</given-names></name><name><surname>Lewis</surname><given-names>WG</given-names></name></person-group><article-title>Influence of a regional centralised upper gastrointestinal cancer service model on patient safety, quality of care and survival</article-title><source>Clin Oncol (R Coll Radiol)</source><year>2013</year><volume>25</volume><fpage>719</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.clon.2013.08.005</pub-id><pub-id pub-id-type="pmid">23994038</pub-id></element-citation></ref></ref-list></back></article>